Effect of Kang'ai injection plus chemotherapy and bevacizumab on clinical efficacy and survival in advanced colorectal cancer
Objective:To observe the effect of Kang'ai injection combined with chemotherapy and bevacizumab on the clinical efficacy and survival in the treatment of patients with advanced colorectal cancer.Methods:Retrospective analysis was conducted in 68 patients of advanced colorectal cancer treated in our hospital between June 2018 and December 2021.The patients were divided into group A(n=34),treated with Kang'ai injection combined with CAPEOX and bevacizumab as the first-line regimen,and group B(n=34),treated with CAPEOX and bevacizumab as the first-line therapy.After 5 cycles of medication,patients in the two groups without progressive disease were given capecitabine maintenance treatment until progressive disease.Then the two groups were observed and compared regarding the curative efficacy,changes of tumor markers,and median progression free survival(mPFS).Results:The objective response rate(ORR)was significantly higher in group A than in group B(67.6%vs.41.2%,P<0.05).The levels of CEA and CA199 were notably decreased in both groups after 5 cycles of treatment compared to pre-medication(P<0.001),and the decrease was dominant in group A(P<0.05).Patients in group A had longer mPFS than those in group B(P<0.05),yet there was no significant difference in the incidence of adverse reactions,including nausea,vomiting and bone marrow suppression between the two groups(P>0.05).Conclusion:Compared with CAPEOX plus bevacizumab regimen,Kang'ai injection combined with chemotherapy and bevacizumab can effectively boost the curative efficacy,inhibit CEA and CA199 levels and improve mPFS,without adding adverse response in the treatment of patients with advanced colorectal cancer.